A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Project: Other project

Project Details

StatusActive
Effective start/end date6/19/206/18/23

Funding

  • Astellas Pharma Global Development Inc: $12,692.31